Correction: ER Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.
作者信息
Guerrero-Zotano Angel L, Stricker Thomas P, Formisano Luigi, Hutchinson Katherine E, Stover Daniel G, Lee Kyung-Min, Schwarz Luis J, Giltnane Jennifer M, Estrada Monica V, Jansen Valerie M, Servetto Alberto, Gavilá Joaquín, Perez-Fidalgo J Alejandro, Lluch Ana, Llombart-Cussac Antonio, Bayar Mohamed Amine, Michiels Stefan, André Fabrice, Arnedos Mónica, Guillem Vicente, Ruiz-Simon Amparo, Arteaga Carlos L
出版信息
Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270.
Abstract
摘要
相似文献
1
Correction: ER Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.更正：对延长新辅助来曲唑治疗耐药的雌激素受体阳性乳腺癌表现出对细胞周期蛋白依赖性激酶4/6抑制剂敏感的E2F4转录程序。
Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270.
2
ER Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.ER 阳性乳腺癌对长期新辅助来曲唑耐药的患者存在 E2F4 转录程序，对 CDK4/6 抑制剂敏感。
Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26.
3
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.雌激素受体共激活因子结合调节剂（ERX-11）增强了 CDK4/6 抑制剂对雌激素受体阳性乳腺癌的活性。
Breast Cancer Res. 2019 Dec 26;21(1):150. doi: 10.1186/s13058-019-1227-8.
4
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.亚洲绝经后雌激素受体（ER）和人表皮生长因子受体2（HER2）阳性乳腺癌患者新辅助来曲唑和拉帕替尼治疗的II期试验[Neo-ALL-IN]：强调肿瘤浸润淋巴细胞、新辅助治疗后ER表达变化以及FES-PET作为潜在的重要生物标志物
Cancer Chemother Pharmacol. 2016 Oct;78(4):685-95. doi: 10.1007/s00280-016-3107-6. Epub 2016 Aug 4.
5
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.依维莫司联合来曲唑对比氟尿嘧啶、表柔比星和环磷酰胺用于激素受体阳性、HER2 阴性乳腺癌的新辅助治疗：一项随机先导试验。
BMC Cancer. 2021 Jul 27;21(1):862. doi: 10.1186/s12885-021-08612-y.
6
Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.CDK4/6抑制剂联合内分泌治疗晚期激素受体阳性（HR+）和人表皮生长因子受体2阴性（HER2-）乳腺癌的药物经济学评价：一项系统综述
Ann Transl Med. 2022 Feb;10(4):233. doi: 10.21037/atm-21-5110.
7
Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.获得性 CDK4/6 抑制剂耐药后 ER 依赖性降低。
Breast Cancer. 2020 Sep;27(5):963-972. doi: 10.1007/s12282-020-01090-3. Epub 2020 Apr 15.
8
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.E2F4预后特征可预测乳腺癌患者对新辅助化疗的病理反应。
BMC Cancer. 2017 May 2;17(1):306. doi: 10.1186/s12885-017-3297-2.
9
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.CDK4/6 抑制剂在美国绝经后女性中用于 HR+/HER2-转移性乳腺癌一线治疗的成本效果分析
Pharmacoeconomics. 2023 Jun;41(6):709-718. doi: 10.1007/s40273-023-01245-y. Epub 2023 Mar 15.
10
Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis.细胞周期蛋白依赖性激酶 4 和 6 抑制剂联合新辅助内分泌治疗雌激素受体阳性早期乳腺癌：系统评价和荟萃分析。
Clin Exp Med. 2023 Jun;23(2):245-254. doi: 10.1007/s10238-022-00814-3. Epub 2022 Mar 19.
引用本文的文献
1
HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.高迁移率族蛋白 B1（HMGB1）是他莫昔芬耐药的关键因素，有可能预测 CDK4/6 抑制剂在乳腺癌中的疗效。
Cancer Sci. 2021 Apr;112(4):1603-1613. doi: 10.1111/cas.14813. Epub 2021 Feb 26.
本文引用的文献
1
ER Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.ER 阳性乳腺癌对长期新辅助来曲唑耐药的患者存在 E2F4 转录程序，对 CDK4/6 抑制剂敏感。
Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26.
Zotero 插件